Related Experiment Video
Updated: Mar 1, 2026
Expression of Recombinant Proteins in the Methylotrophic Yeast Pichia pastoris
Published on: February 25, 2010
Yeast Expressing Gp43 Protein as a Vaccine Against Paracoccidioides brasiliensis Infection
Aline Ferreira Oliveira1,2,3, Paulo S R Coelho4
1Departamento de Biologia Celular e Molecular e Bioagentes Patogênicos, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Avenida dos Bandeirantes 3900, Ribeirão Preto, SP, 14049-900, Brasil.
Abstract:
Paracoccidioidomycosis (PCM) represents the most frequent systemic mycosis in Latin American. The disease is caused by the pathogenic thermally dimorphic fungus Paracoccidioides brasiliensis, and is initially characterized by pulmonary lesions, which can subsequently disseminate to other organs, resulting in secondary injuries. Although its high incidence, there is no commercially available vaccine against fungal diseases. A novel strategy, using Saccharomyces cerevisiae yeast as a vehicle for immunization against PCM, was recently successfully described. Herein, we describe strategies for the construction of the suitable S. cerevisiae vaccine, and protocols of administration and evaluation of the efficacy of the vaccine against experimental PCM.
Insights
Researchers developed a novel Saccharomyces cerevisiae vaccine to combat Paracoccidioidomycosis (PCM), a common fungal infection. This study details vaccine construction, administration, and efficacy testing against experimental PCM.
Area of Science:
- Medical Mycology
- Infectious Diseases
- Vaccine Development
Background:
- Paracoccidioidomycosis (PCM) is a prevalent systemic mycosis in Latin America, caused by the fungus Paracoccidioides brasiliensis.
- The infection typically begins with pulmonary lesions and can disseminate to other organs, causing secondary damage.
- Currently, no commercial vaccine is available for PCM, despite its high incidence.
Purpose of the Study:
- To describe strategies for constructing a Saccharomyces cerevisiae-based vaccine for Paracoccidioidomycosis.
- To outline protocols for administering and evaluating the efficacy of this novel vaccine against experimental PCM.
Main Methods:
- Construction of a Saccharomyces cerevisiae vaccine vehicle.
- Administration of the vaccine in an experimental model.
- Evaluation of vaccine efficacy against experimental Paracoccidioidomycosis.
Main Results:
- Successful construction of a suitable S. cerevisiae vaccine.
- Established protocols for vaccine administration and efficacy evaluation.
- Demonstrated potential of the S. cerevisiae vaccine in experimental PCM.
Conclusions:
- Saccharomyces cerevisiae serves as a promising vaccine vehicle for Paracoccidioidomycosis.
- The developed strategies provide a foundation for further vaccine development and testing.
- This approach offers a novel immunization strategy against a significant fungal disease.
